Immunothrombosis—immune-mediated activation of coagulation—is protective against
pathogens, but excessive immunothrombosis can result in pathological thrombosis and …

Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …

Abstract The Coronavirus disease‐2019 (COVID‐19) pandemic continues, and the death toll
continues to surge. This meta‐analysis aimed to determine the efficacy of anakinra on …

The Arg/N-degron pathway, which is involved in the degradation of proteins bearing an N-
terminal signal peptide, is connected to p62/SQSTM1-mediated autophagy. However, the …

Summary Background The SAVE-MORE trial demonstrated that anakinra treatment in
COVID-19 pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels …

Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory
failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation …

Abstract Introduction and Objective. In COVID-19, the rapid prediction of the severity of a
patient's condition using modern biomarkers can accelerate the implementation of …

We aimed to develop presepsin as a marker of diagnosis of severe infections of either
bacterial and viral origin. The derivation cohort was recruited from 173 hospitalized patients …

Importance COVID-19 pneumonia is often associated with hyperinflammation. The efficacy
and safety of anakinra in treating patients with severe COVID-19 pneumonia and …

The COVID-19 pandemic has been a global medical emergency with a significant socio-
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …